Promising drug targets rare cancer in small trial
NCT ID NCT07104331
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a drug called nab-sirolimus in 41 people with a rare cancer called epithelioid hemangioendothelioma (EHE) that is growing or causing symptoms. The drug is given through an IV twice per cycle. The main goal is to see if it can shrink tumors. Researchers will also track how long the benefit lasts and how long people live without the cancer getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nab-sirolimus (a form of the drug sirolimus, given as an IV infusion)
What this could lead to
If it works, this could point toward a new treatment option for people with EHE, a rare blood vessel cancer, by slowing or shrinking tumors.
What could go wrong
This is a small, early-phase trial with only 41 participants, so results may not apply to everyone. The drug may cause side effects like mouth sores or low blood counts, and it may not shrink tumors enough to be considered effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIOID HEMANGIOENDOTHELIOMA (EHE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
NOT_YET_RECRUITINGBoston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Sloan Kettering Institute for Cancer Research
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Stanford University
RECRUITINGStanford, California, 94305, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Colorado
NOT_YET_RECRUITINGAurora, Colorado, 80203, United States
-
Washington University St. Louis
RECRUITINGSt Louis, Missouri, 63130, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••